Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older

Journal of the American Geriatrics Society

Volumn 59, Issue 12, 2011, Pages 2386-2387

  Fasano, Alfonso ^a,b   Guidubaldi, Arianna ^a   De Nigris, Francesca ^a   Bentivoglio, Anna Rita ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ROTIGOTINE;

AGED; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HALLUCINATION; HUMAN; HYPOTENSION; LETTER; MALE; MONOTHERAPY; PARKINSON DISEASE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; PARKINSON DISEASE; PROSPECTIVE STUDIES; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84055198460     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03689.x     Document Type: Letter

References (4)

1. Reynolds NA, Wellington K, Easthope SE,. Rotigotine in Parkinson's disease. CNS Drugs 2005; 19: 973-981.
2. Olanow CW, Watts RL, Koller WC,. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology 2001; 56: S1-S88. (Pubitemid 32532291)
3. Wentrup A, Oertel WH, Dodel R,. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther 2009; 2: 245-254.
4. Giladi N, Fichtner A, Poewe W, Boroojerdi B,. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm. 2010; 117: 1395-1399.